ClinicalTrials.gov record
Completed Phase 2 Interventional

Combination Chemotherapy and Bone Marrow and/or Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma

ClinicalTrials.gov ID: NCT00002521

Public ClinicalTrials.gov record NCT00002521. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 11, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

HIGH-DOSE CYCLOPHOSPHAMIDE, ETOPOSIDE, AND CISPLATIN (CEP) WITH RESCUE BY AUTOLOGOUS BONE MARROW OR AUTOLOGOUS PERIPHERAL BLOOD STEM CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NON-HODGKIN'S LYMPHOMA (INTERMEDIATE AND HIGH-GRADE HISTOLOGIES)

Study identification

NCT ID
NCT00002521
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Temple University
Other
Enrollment
Not listed

Conditions and interventions

Conditions

Interventions

  • autologous bone marrow transplantation Procedure
  • bone marrow ablation with stem cell support Procedure
  • cisplatin Drug
  • cyclophosphamide Drug
  • etoposide Drug
  • peripheral blood stem cell transplantation Procedure
  • radiation therapy Radiation
  • syngeneic bone marrow transplantation Procedure

Procedure · Drug · Radiation

Eligibility (public fields only)

Age range
15 Years to 70 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 1993
Primary completion
Jan 31, 2000
Completion
Jan 31, 2000
Last update posted
Sep 30, 2010

1993 – 2000

United States locations

U.S. sites
1
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Fox Chase - Temple Cancer Center Philadelphia Pennsylvania 19111-2442

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00002521, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Sep 30, 2010 · Synced May 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00002521 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →